IRIS
PICCIOTTO, ANTONINO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 9.107
Totale 9.107
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 9.107
Totale 9.107
Salva come PNG Salva come JPEG
Città #
Genova 7.457
Rapallo 954
Genoa 655
Vado Ligure 30
Bordighera 11
Totale 9.107
Salva come PNG Salva come JPEG
Nome #
Non-antigen-specific CD8(+) T suppressor lymphocytes in diseases characterized by chronic immune responses and inflammation. 222
Hepatitis G virus infection in haemodialysis and in peritoneal dialysis patients. 175
Epidemiological and clinical features of hepatitis delta in HBsAg-positive patients by HIV status. 150
A new assay for hepatitis C virus (HCV) core antigen detection: an alternative to nucleic acid technologies in positive or indeterminate anti-HCV subjects? 142
Peripheral blood serum markers for apoptosis and liver fibrosis: Are they trustworthy indicators of liver realness? 141
S-adenosil-L-methionine is able to reverse the immunosuppressive effects of chenodeoxycholic acid in vitro. 139
Circadian monitoring of gastric juice mutagenicity. 137
Mutagenicity of cimetidine in nitrite-enriched human gastric juice. 135
Peripheral blood cytopaenia limiting initiation of treatment in chronic hepatitis C patients otherwise eligible for antiviral therapy 135
Autoimmune intrahepatic cholangiopathy associated with antiphospholipid antibody syndrome 133
Behavior of soluble HLA class I antigens in patients with chronic hepatitis C during interferon therapy: an early predictor marker of response? 128
'Emergency exit' of bone-marrow-resident CD34+ DNAM-1 bright CXCR4+-committed lymphoid precursors during chronic infection and inflammation 126
Measurement of sorafenib plasma concentration by high-performance liquid chromatography in patients with advanced hepatocellular carcinoma: is it useful the application in clinical practice? A pilot study 126
Anti-hepatitis C virus antibodies and hepatitis C virus viraemia in haemodialysis patients 123
Circadian reduction of chromium in the gastric environment. 123
Increased natural cytotoxicity receptor expression and relevant IL-10 production in NK cells from chronically infected viremic HCV patients 123
Activating NK cell receptor expression/function (NKp30, NKp46, DNAM-1) during chronic viraemic HCV infection is associated with the outcome of combined treatment. 123
Is hepatic ultrasonography a valid alternative tool to liver biopsy? Report on 507 cases studied with both techniques. 122
T cells from patients with chronic liver diseases: abnormalities in PHA-induced expression of HLA class II antigens and in autologous mixed-lymphocyte reactions. 122
Long-term outcomes of direct acting antivirals in post-transplant advanced hepatitis C virus recurrence and fibrosing cholestatic hepatitis 122
Behavior of soluble HLA-A, -B, -C and HLA-G molecules in patients with chronic hepatitis C virus infection undergoing pegylated interferon-α and ribavirin treatment: potential role as markers of response to antiviral therapy 121
A case of drug rash with eosinophilia and systemic symptoms (DRESS) induced by telaprevir associated with HHV-6 active infection 121
Soluble apoptosis molecules in primary biliary cirrhosis: analysis and commitment of the Fas and tumour necrosis factor-related apoptosis-inducing ligand systems in comparison with chronic hepatitis C. 118
Successful antiviral therapy determines a significant decrease in squamous cell carcinoma antigen-associated (SCCA) variants' serum levels in anti-HCV positive cirrhotic patients. 118
Increased beta2-microglobulin-free HLA class I heavy chain serum levels in the course of immune responses to viral antigens and to mismatched HLA antigens. 118
Comparison between laparoscopy, ultrasonography, and computed tomography in widespread and localized liver diseases. 115
Lack of correlation between serum anti-HBcore detectability and hepatocellular carcinoma in patients with HCV-related cirrhosis 113
Long-term interferon alfa-2b retreatment of relapsing patients with chronic hepatitis C. 111
Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy. 111
HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels 111
Single bedtime dose of famotidine: assessment of its antisecretory action by 24-hour intragastric pH monitoring. 110
Inherent transcriptional signatures of NK cells are associated with response to IFNΑ+rivabirin therapy in patients with Hepatitis C Virus 110
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 109
Biopsychosocial predictors of interferon-related depression in patients with Hepatitis C 108
Predictive factors for response to Peginterferon-Alpha and ribavirin treatment of chronic HCV infection in patients aged 65 years and more 108
Pegylated interferon and ribavirin in re-treatment of responder-relapser HCV patients. 107
Peginterferon alfa-2b and Ribavirin: Effective in Patients With Hepatitis C Who Failed Interferon alfa/Ribavirin Therapy. 106
Monotherapy with Pegylated Interferon Alpha-2a in Hemodialyzed Patients with Chronic Hepatitis C 105
Clearance kinetics of hepatitis C virus under different antiviral therapies. 105
Antiviral activity of amantadine in elderly patients with chronic hepatitis C 105
A single-blind pilot study comparing standard and half bedtime doses of ranitidine in the short-term healing of duodenal ulcer. 104
Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. 104
Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies 104
Clinical and virological survey of patients with hepatitis B surface antigen in an Italian region: clinical considerations and disease burden 103
Virological and biochemical responses to interferon-a in chronic hepatitis C 100
Sustained virological response to pegylated interferon and ribavirin is maintained during long-term follow-up of chronic hepatitis C patients. 100
Serum lamivudine levels in the presence of a lamivudine-resistant HBV mutant 99
Macroamylasemia: a possible cause of unexplained hyperamylasemia in rheumatoid arthritis. 99
Liver transplantation in type III von Willebrand disease 99
TT virus infection in haemodialysis patients 98
Porphyrin Elevation in a Patient on Treatment With Simeprevir: Could It Be a Possible Explanation for Simeprevir-Associated Photosensitivity? 98
Soluble tumor necrosis factor-related ligand (sTRAIL) levels and kinetics during antiviral treatment in chronic hepatitis C 97
Interferon retreatment in chronic hepatitis C: wich patients to choose, and what schedule to use 96
Kinetics of soluble tumour necrosis factor (TNF)-alpha receptors and cytokines in the early phase of treatment for chronic hepatitis C: comparison between interferon (IFN)-alpha alone, IFN-alpha plus amantadine or plus ribavirin. 95
Hepatitis C in the elderly: A multicentre cross-sectional study by the Italian Association for the Study of the Liver 95
HOMA, BMI, and serum leptin levels variations during antiviral treatment suggest virus-related insulin resistance in noncirrhotic, nonobese, and nondiabetic chronic hepatitis C genotype 1 patients 92
Predictive value of on-treatment response during full-dose antiviral therapy of patients with hepatitis C virus cirrhosis and portal hypertension. 91
Are clinical patterns of dyspepsia a valid guideline for appropriate use of endoscopy? A report on 2253 dyspeptic patients. 90
Elevations in ALT levels late the course of antiviral therapy in HCV-RNA negative patients are associated with virological relapse 87
Effects of Interferon therapy on monoethylglycinexylidide formation in patients with chronic active hepatitis C 86
Diabetic hepatosclerosis presenting with severe cholestasis 86
Medical report type in liver transplantation as a quality system document: new prospects for computerization. 86
Interferon beta-1a alone or in combination with ribavirin: a randomized trial to compare efficacy and safety in chronic hepatitis C. 85
First experimental proof of Proton Boron Capture Therapy (PBCT) to enhance protontherapy effectiveness 85
Prospective evaluation of primary infection due to HCV, HGV or TTV in children with newly diagnosed neoplasia. 84
The Italian compassionate use of sofosbuvir in HCV patients waitlisted for liver transplantation: A national real-life experience 83
Treatment of hepatitis C virus infection with direct-acting antiviral drugs is safe and effective in patients with hemoglobinopathies 83
Amantadine: a different approach. 82
Hepatitis C recurrence: Split liver versus whole size graft. 78
Continuous lamivudine treatment in an OLT patient despite the appearance of HBV resistant strain: longitudinal analysis. 77
Chronic hepatitis C. New therapeutic strategies. 77
A significant proportion of patients with chronic hepatitis B who are candidates for antiviral treatment are untreated: a region-wide survey in Italy 75
Prevalence and Undertreatment of Prothrombotic Risk in Advanced Forms of Liver Disease 73
Human leukocyte antigen polymorphisms in Italian primary biliary cirrhosis: a multicenter study of 664 patients and 1992 healthy controls. 72
EVALUATION OF HEPATIC FIBROSIS WITH TRANSIENT ELASTOGRAPHY (FIBROSCAN) AND APRI SCORE IN PATIENTS WITH SYSTEMIC SCLEROSIS AND ITS CORRELATION WITH PULMONARY, CARDIAC, RENAL AND ESOPHAGEAL INVOLVEMENT 71
Initial high dose of lamivudine delays the appearance of viral resistance in chronic hepatitis B patients 70
Therapeutic management of chronic hepatitis B in clinical Practice: a region-wide survey. 70
Serum intercellular adhesion molecule-1 and long-term response to IFN-alpha2b therapy in chronic hepatitis C 68
Probability of non-response during interferon therapy in patients with chronic hepatitis C 66
Metabolic activation of food hepatocarcinogens in hepatitis B virus-infected humans and animals. 66
Postprandial serum bile acids after ursodeoxycholic acid. A possible test of intestinal absorption? 66
Predictability and survival in liver replantransplantation: Monocentric experience 66
Cost-effectiveness of pretransplant sofosbuvir for preventing recurrent hepatitis C virus infection after liver transplantation 65
Evaluation of a new hepatitis C virus sequecing assay as a routine method for genotyping 63
Use of Victoria blue in the detection of intrahepatocyte HBs Ag: comparison with other methods. 61
Biochemical scores could reflect histological activity in chronic hepatitis C 60
Detection of anti-HCV IgM antibodies in patients with chronic hepatitis C treated with interferon 57
Hepatic Elastometry and Glissonian Line in the Assessment of Liver Fibrosis 57
Pityriasis rosea in a hepatitis b-positive patient treated with pegylated interferon α2a: Report of a case and review of the literature 57
Iodized oil pleural effusion in a patient previously treated with transarterial chemoembolization for hepatocellular carcinoma 53
Soluble beta2-mu-associated and beta2-mu-free HLA class I heavy chain serum levels in interferon-alpha nonresponder chronic hepatitis C patients. Markers of immune activation, and response to antiviral retreatment. 48
Individualized treatment of genotype 1 Naïve patients: An Italian multicenter field practice experience 46
Effect of a common missense variant in LIPA gene on fatty liver disease and lipid phenotype: New perspectives from a single-center observational study 30
Role of dietary intervention in patients with metabolic syndrome and {NAFLD}-{NASH} 17
Totale 9.197
Salva come PNG Salva come JPEG
Categoria #
all - tutte 24.756
article - articoli 24.526
book - libri 0
conference - conferenze 230
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 49.512
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.613 0 85 137 163 236 312 403 216 263 436 275 87
2020/2021750 39 73 80 51 62 70 24 81 55 100 54 61
2021/20221.168 36 63 73 145 47 81 69 262 92 104 47 149
2022/20231.134 115 105 11 107 175 192 3 95 205 11 105 10
2023/2024463 19 80 8 59 32 63 25 30 30 9 40 68
2024/202556 52 4 0 0 0 0 0 0 0 0 0 0
Totale 9.197